<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000643596">
  <TermName>anti-TRAIL R1-mAb</TermName>
  <TermPronunciation>(AN-tee ...)</TermPronunciation>
  <TermDefinition>
    <DefinitionText>A substance being studied in the treatment of some types of cancer. It binds to a protein called TRAIL R1 on the surface of some tumor cells.  This may kill the tumor cells. Anti-TRAIL R1-mAb is a type of monoclonal antibody. Also called HGS-ETR1 and mapatumumab.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <MediaLink ref="CDR0000725782" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;anti-TRAIL R1-mAb&quot;" language="en" id="_3"/>
  <MediaLink ref="CDR0000815623" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;AcM anti-TRAIL R1&quot;" language="es" id="_4"/>
  <SpanishTermName>AcM anti-TRAIL R1</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>Sustancia en estudio para el tratamiento de ciertos tipos de cáncer. Se une a una proteína llamada TRAIL R1 que se encuentra en la superficie de algunas células tumorales, y en ocasiones las destruye. El AcM anti-TRAIL R1 es un tipo de anticuerpo monoclonal. También se llama HGS-ETR1 y mapatumumab.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateFirstPublished>2009-05-19</DateFirstPublished>
</GlossaryTerm>
